Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
Abstract Background Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials...
Main Authors: | Xiaolei Zhu, Shenhong Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Clinical Hypertension |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40885-019-0116-x |
Similar Items
-
Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis
by: Xiaolei Zhu, et al.
Published: (2019-04-01) -
Usage, effectiveness and safety of abiraterone in prostate cancer
by: J. M. Caro Teller, et al.
Published: (2014-03-01) -
Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01) -
Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01) -
Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
by: Simon Rauch, et al.
Published: (2016-06-01)